{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:58:57Z","timestamp":1790769537277,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clml.2026.09.005","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:18:45Z","timestamp":1788949125000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Blastic Plasmacytoid Dendritic Cell Neoplasm in the Dual CD123-targeted Therapy Era: A Clinical Decision Review of Treatment Selection, Sequencing, CNS Management, and Transplant Integration"],"prefix":"10.1016","author":[{"given":"Xichang","family":"Fei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.09.005_bib0001","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.09.005_bib0002","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.005_bib0003","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.2022017865","article-title":"North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need","volume":"141","author":"Pemmaraju","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.005_bib0004","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.2024024262","article-title":"How I treat blastic plasmacytoid dendritic cell neoplasm","volume":"145","author":"Kharfan-Dabaja","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.005_bib0005","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/ajh.27737","article-title":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN): 2025 update on diagnosis, pathophysiology, risk assessment, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.09.005_sbref0006","series-title":"FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy","year":"2026"},{"key":"10.1016\/j.clml.2026.09.005_bib0007","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1200\/JCO-25-02083","article-title":"Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm","volume":"44","author":"Pemmaraju","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.09.005_bib0008","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.09.005_bib0009","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.22.00034","article-title":"Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm","volume":"40","author":"Pemmaraju","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.09.005_sbref0010","series-title":"ELZONRIS (tagraxofusp-erzs) injection: prescribing information","year":"2023"},{"key":"10.1016\/j.clml.2026.09.005_bib0011","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00277-023-05587-7","article-title":"Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations","volume":"103","author":"Shumilov","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.09.005_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3960\/jslrt.24069","article-title":"Diagnostic approach to blastic plasmacytoid dendritic cell neoplasm: historical perspectives and current understanding","volume":"65","author":"Sakamoto","year":"2025","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.clml.2026.09.005_bib0013","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3324\/haematol.2020.247569","article-title":"Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm","volume":"106","author":"Wang","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.09.005_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100253","article-title":"Comparison and development of immunohistochemical diagnostic criteria for blastic plasmacytoid dendritic cell neoplasm","volume":"36","author":"Sakamoto","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2026.09.005_bib0015","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.3324\/haematol.2020.253740","article-title":"Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape","volume":"106","author":"Zalma\u00ef","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.09.005_bib0016","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/s41375-022-01538-9","article-title":"Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients","volume":"36","author":"Khanlari","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.09.005_bib0017","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-022-00699-1","article-title":"Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm","volume":"12","author":"K\u00fcnstner","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.clml.2026.09.005_bib0018","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-023-06156-8","article-title":"Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin","volume":"618","author":"Griffin","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.clml.2026.09.005_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13235888","article-title":"Integrated clinical genotype-phenotype characteristics of blastic plasmacytoid dendritic cell neoplasm","volume":"13","author":"Yin","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2026.09.005_bib0020","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6004\/jnccn.2023.7026","article-title":"Blastic plasmacytoid dendritic cell neoplasm","volume":"21","author":"Jain","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.clml.2026.09.005_bib0021","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/bloodadvances.2021006645","article-title":"Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD","volume":"6","author":"Pemmaraju","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.09.005_bib0022","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1002\/ajh.26417","article-title":"Venetoclax and hypomethylating agents in older\/unfit patients with blastic plasmacytoid dendritic cell neoplasm","volume":"97","author":"Gangat","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.09.005_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100086","article-title":"Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN","volume":"2","author":"Pemmaraju","year":"2025","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.clml.2026.09.005_bib0024","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s00277-025-06221-4","article-title":"Venetoclax and hypomethylating agents versus tagraxofusp in older patients with blastic plasmacytoid dendritic cell neoplasm","volume":"104","author":"Lee","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.09.005_bib0025","doi-asserted-by":"crossref","first-page":"10174","DOI":"10.18632\/oncotarget.7101","article-title":"Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy","volume":"7","author":"Mart\u00edn-Mart\u00edn","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2026.09.005_bib0026","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.2021011817","article-title":"Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm","volume":"138","author":"Pemmaraju","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.005_bib0027","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3324\/haematol.2022.280843","article-title":"Treatment of leptomeningeal disease in blastic plasmacytoid dendritic cell neoplasm following tagraxofusp-erzs induction","volume":"107","author":"Vangala","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.09.005_bib0028","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41409-021-01478-5","article-title":"Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"57","author":"Bashir","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.09.005_bib0029","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1182\/bloodadvances.2023011308","article-title":"Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis","volume":"7","author":"Murthy","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.09.005_bib0030","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/j.clml.2023.12.010","article-title":"Recent advances in the biology and CD123-directed treatment of blastic plasmacytoid dendritic cell neoplasm","volume":"24","author":"Pemmaraju","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.09.005_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092287","article-title":"CD123 and more: how to target the cell surface of blastic plasmacytoid dendritic cell neoplasm","volume":"14","author":"B\u00f4le-Richard","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2026.09.005_bib0032","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1080\/10428194.2025.2557505","article-title":"Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm","volume":"66","author":"Lane","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.09.005_bib0033","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/10428194.2024.2305288","article-title":"Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations","volume":"65","author":"Pemmaraju","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.09.005_bib0034","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1007\/s00277-025-06493-w","article-title":"Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-na\u00efve patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European named Patient Program","volume":"104","author":"Herling","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.09.005_bib0035","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1080\/10428194.2025.2553862","article-title":"Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm","volume":"66","author":"Angelucci","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.09.005_bib0036","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s12185-025-04151-5","article-title":"A phase I\/II study of tagraxofusp in Japanese patients with blastic plasmacytoid dendritic cell neoplasm","volume":"123","author":"Yokota","year":"2026","journal-title":"Int. J. Hematol"},{"key":"10.1016\/j.clml.2026.09.005_bib0037","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","article-title":"Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2026.09.005_bib0038","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2026033906","article-title":"Tagraxofusp, azacitidine, and venetoclax in blastic plasmacytoid dendritic cell neoplasm","author":"Lane","year":"2026","journal-title":"Blood"},{"issue":"Suppl. 16","key":"10.1016\/j.clml.2026.09.005_bib0039","article-title":"A phase II trial of tagraxofusp, hyper-CVAD, and venetoclax for patients with newly diagnosed or relapsed\/refractory BPDCN","volume":"44","author":"Goulart","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.09.005_bib0040","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1172\/JCI128571","article-title":"DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance","volume":"129","author":"Togami","year":"2019","journal-title":"J Clin Investig"},{"key":"10.1016\/j.clml.2026.09.005_bib0041","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.288663","article-title":"Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm: assessing spatial response and unraveling resistance mechanisms","author":"Poussard","year":"2026","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.09.005_bib0042","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/s41375-023-01968-z","article-title":"Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies","volume":"37","author":"Cuglievan","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.09.005_bib0043","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241251602","article-title":"A systematic literature review of 74 Chinese blastic plasmacytoid dendritic cell neoplasm patients","volume":"15","author":"Gong","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2026.09.005_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106928","article-title":"CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): clinicopathological insights","volume":"121","author":"Pemmaraju","year":"2022","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2026.09.005_bib0045","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/bloodadvances.2024014590","article-title":"Venetoclax\u2013proteasome inhibitor\u2013dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm","volume":"9","author":"Khalife-Hachem","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.09.005_bib0046","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1182\/bloodadvances.2021005802","article-title":"Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey","volume":"5","author":"Valentini","year":"2021","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502603291X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502603291X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:19:20Z","timestamp":1790767160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502603291X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"alternative-id":["S215226502603291X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blastic Plasmacytoid Dendritic Cell Neoplasm in the Dual CD123-targeted Therapy Era: A Clinical Decision Review of Treatment Selection, Sequencing, CNS Management, and Transplant Integration","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}